Nachrichten zur ASTRAZENECA DL-,25 SP.ADR Aktie

AstraZeneca Plc (AZN) Q3 2024 Earnings Call Transcript

AZN earnings call for the period ending September 30, 2024.…

AstraZeneca PLC 2024 Q3 - Results - Earnings Call Presentation

…

AstraZeneca PLC (AZN) Q3 2024 Earnings Call Transcript

…

AstraZeneca Talks Up US Growth as China Problems Fester

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business slows amid a probe…

AstraZeneca Lifts Outlook, Plans $3.5B US Investment

British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it…

Trending tickers: The latest investor updates on Coinbase, Tesla, AstraZeneca, Metro Bank and SoftBank

The latest investor updates on stocks that are trending on Tuesday.…

ROUNDUP: Astrazeneca hebt Jahresziele erneut - Milliardeninvestition in den USA

CAMBRIDGE (dpa-AFX) - Eine hohe Nachfrage vor allem nach seinen Medikamenten gegen Krebs und seltene Krankheiten sorgt beim Pharmakonzern Astrazeneca…

AstraZeneca raises 2024 outlook on strong Q3 By Investing.com

AstraZeneca raises 2024 outlook on strong Q3…

AstraZeneca shares present an opportunity after strong Q3 results

The UK’s second-largest listed company by market cap (at the time of writing) presents an opportunity for investors after releasing…

Astrazeneca plant Milliardeninvestionen in USA - Attraktives Geschäftsumfeld

CAMBRIDGE (dpa-AFX) - Nur wenige Tage nach den richtungsweisenden US-Präsidentschaftswahlen hat der britisch-schwedische Pharmakonzern Astrazeneca dort milliardenschwere Investitionen angekündigt.…

AstraZeneca lifts 2024 revenue and profit forecast after Q3 beat By Reuters

AstraZeneca lifts 2024 revenue and profit forecast after Q3 beat…

AstraZeneca invests $3.5 billion in US

12 November 2024 AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States AstraZeneca today announces $3.5 billion of capital investment…

Dato-DXd new BLA submitted, NSQ BLA withdrawn

12 November 2024 Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small…

9M and Q3 2024 Results

AstraZeneca 12 November 2024 9M and Q3 2024 results Upgrade to full year 2024 guidance underpinned by strong underlying growth momentum Revenue and EPS…

AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US

AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second…

AstraZeneca’s China-Fueled Plunge May Be Difficult to Shake Off

AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday…

AstraZeneca: Contrarian Buy After The China Challenge (Rating Upgrade)

…

AstraZeneca Says Current, Former Executives Involved in China Probe

Two current and two former senior AstraZeneca Plc executives in the group’s China unit are under investigation in a probe…

AstraZeneca Aktie: Kursrückgang übertrieben

Toronto (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von BMO Capital Markets: 1. Überblick über die Situation AstraZeneca plc (ISIN: GB0009895292, WKN: 886455, Ticker-Symbol: ZEG, London…

ANALYSE-FLASH: Deutsche Bank Research hebt Astrazeneca auf Hold

FRANKFURT (dpa-AFX) - Deutsche Bank Research hat Astrazeneca bei einem unveränderten Kursziel von 10500 Pence von "Sell" auf "Hold"…

AstraZeneca Aktie: China-Bedenken übertrieben - Kursrückgang als Kaufchance!

Charlotte (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von BofA Securities: Aktuelle Bewertung Die Analysten von BofA Securities stufen die Aktie von AstraZeneca plc (ISIN: GB0009895292,…

Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 Earnings

AstraZenecas key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the…

AstraZeneca shares fall on report of potential China probe fallout

AstraZeneca shares recorded their worst day since March 2020.…

FIVE at FIVE: Primark profits up; AstraZeneca, FTSE 100 slip; Trump trades higher; ASOS losses escalate

1. Primark owner ABF hikes dividend, buyback as profit jumps “We delivered a substantial improvement in profitability, excellent cash generation…

AstraZeneca sheds £15bn in value on weight loss drug data, China fraud report

AstraZeneca PLC (LSE:AZN) shed £15 billion in value on Tuesday following early data on its weight loss drugs and reports dozens…

GOLDMAN SACHS stuft ASTRAZENECA auf Buy

NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für Astrazeneca mit einem Kursziel von 16046 Pence…

UBS stuft ASTRAZENECA auf Sell

ZÜRICH (dpa-AFX Analyser) - Die schweizerische Großbank UBS hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 11.300…

Total Voting Rights

1 November 2024 15:00 GMT Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

AstraZeneca says its China operations president under investigation

AstraZenecas China president is under investigation and is cooperating with Chinese authorities, the company said on Wednesday, sending shares down…

AZN China President under investigation

This announcement contains inside information 30 October 2024 AstraZeneca China President currently under investigation Leon Wang, Executive Vice President International and AstraZeneca China…

AstraZeneca Receives CHMPs Approval for Wainzua in Europe

The CHMP recommends approval for AZNs Wainzua for treating polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.…

Wainzua recommended for approval in the EU

21 October 2024 Wainzua (eplontersen) recommended for approval in the EU by CHMP for the treatment of adult patients with polyneuropathy associated…

US Rheumatologists and Dermatologists Report Over Half of their Dermatomyositis Patients Not Optimally Managed, According to Spherix Global Insights

Although CSL Behring’s Hizentra (IgPro20) is touted as a key pipeline agent to watch, rheumatologists currently prefer AstraZeneca’s Saphnelo (anifrolumab),…

The Zacks Analyst Blog Highlights AstraZeneca, Accenture, AT&T and National Presto Industries

AstraZeneca, Accenture, AT&T and National Presto Industries are part of the Zacks top Analyst Blog.…

Top Research Reports for AstraZeneca, Accenture & AT&T

Todays Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), Accenture plc (ACN) and AT&T…

AstraZeneca reports positive results for Airsupra v. albuterol study

…

AstraZeneca licenses lipid lowering Lp(a) asset

7 October 2024 AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy AstraZeneca has entered into an exclusive…

AstraZeneca and Gilead Sciences merger would be the biggest in the pharma history

…

Avillion announces positive high-level results from Phase III BATURA trial with AstraZeneca’s inhaled anti-inflammatory medication Airsupra in asthma patients

London, UK, 7 October 2024 – Avillion Life Sciences Ltd (“Avillion”) announces that the ongoing BATURA Phase IIIb trial evaluating…

dpa-AFX ProFeed